Large employers are increasingly offering health benefits that include GLP-1 receptor agonists-medications initially ⁤developed for ‍diabetes⁣ that⁢ also promote weight loss-but rising costs⁣ are prompting many to re-evaluate their coverage policies. ⁤‍ Recent discussions with benefits leaders reveal a growing concern about the financial sustainability of widespread access to these drugs.

Cost Concerns drive coverage Adjustments

As of late 2025, a meaningful number of employers are considering scaling back benefits for GLP-1 agonists specifically for⁣ weight loss, or are implementing stricter requirements for coverage. These adjustments aim to manage expenses while still providing access to medically necessary treatments. The findings stem from analysis of the 2025 KFF Employer ⁣Health Benefits Survey, ⁤which included insights from focus groups held throughout the summer and fall of 2025.

Extensive Employer Input

The survey incorporated feedback⁤ from human resources directors and benefits managers representing over ⁣100 companies across the United States. Collectively, these organizations provide health coverage to more then 250,000 ⁤employees. The focus group discussions provided a nuanced understanding of the challenges employers⁤ face when balancing employee health needs with budgetary constraints.

Further data and detailed analysis on ⁤health costs, including employer perspectives, are available from the Peterson-KFF Health ⁤System tracker, a leading resource for monitoring the U.S. health system’s performance.